Sophiris Bio, Inc. (SPHS) Set to Announce Quarterly Earnings on Tuesday

Sophiris Bio, Inc. (NASDAQ:SPHS) is set to issue its quarterly earnings data on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Shares of Sophiris Bio, Inc. (NASDAQ:SPHS) opened at 2.16 on Tuesday. The firm’s market cap is $65.04 million. The firm’s 50-day moving average price is $2.26 and its 200-day moving average price is $2.24. Sophiris Bio, Inc. has a one year low of $1.80 and a one year high of $3.24.

An institutional investor recently raised its position in Sophiris Bio stock. Vanguard Group Inc. boosted its holdings in Sophiris Bio, Inc. (NASDAQ:SPHS) by 1.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 731,437 shares of the biopharmaceutical company’s stock after buying an additional 7,600 shares during the quarter. Vanguard Group Inc. owned 2.43% of Sophiris Bio worth $1,609,000 as of its most recent SEC filing. 5.78% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Sophiris Bio, Inc. (SPHS) Set to Announce Quarterly Earnings on Tuesday” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/10/31/sophiris-bio-inc-sphs-set-to-announce-quarterly-earnings-on-tuesday.html.

Several brokerages recently commented on SPHS. Maxim Group set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a report on Monday, October 2nd. HC Wainwright set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a report on Friday, August 11th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $6.60.

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Earnings History for Sophiris Bio (NASDAQ:SPHS)

What are top analysts saying about Sophiris Bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sophiris Bio Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit